Бевацизумаб (Авастин®) в терапии опухолей мозга. Обзор литературы
Автор: Щербенко Олег Ильич
Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr
Рубрика: Обзоры
Статья в выпуске: 3 т.12, 2012 года.
Бесплатный доступ
Представлен обзор литературы, посвященный результатам использования Бевацизумаба (Авастина ®) при опухолях головного мозга. Большинство опубликованных работ посвящено применению Бевацизумаба при рецидивах и резистентных формах злокачественных глиом у взрослых, и небольшое число посвящено использованию препарата в таких же ситуациях у детей и при первичном химиолучевом лечении глиом у взрослых. В результате применения Бевацизумаба достигнуто увеличение сроков жизни больных без прогрессирования опухоли, но рост показателей выживаемости получен только при использовании препарата в качестве лечебного комплекса первой линии в сочетании с другими химиопрепаратами и лучевой терапией. Бевацизумаб проявил способность уменьшать перитуморальный отек, снижая потребность в применении кортикостероидов. Осложнения в виде тромбофлебитов, кровоизлияний, артериальной гипертензии, замедленного заживления ран и миелодепрессии наблюдаются сравнительно редко и, как правило, не носят фатального характера. Полученные данные свидетельствуют о целесообразности дальнейших исследований с применением Бевацизумаба при химиолучевом послеоперационном лечении первичных больных злокачественными глиомами.
Дети, опухоли мозга, бевацизумаб (авастин), bevaсizumab (avastin®)
Короткий адрес: https://sciup.org/14955340
IDR: 14955340
Bevacizumab (Avastin®) in therapy of tumors of a brain
A review of the literature on the outcome of the use of Вevacizumab (Avastin ®) - for brain tumors. Most published papers are devoted to the use of bevacizumab in recurrent and resistant forms of malignant gliomas in adults and a small number of dedicated use of the drug in the same situations in children and in primary chemoradiation therapy of gliomas in adults. As a result of Bevaсizumab achieved lengthening of life of patients without tumor progression, but the increase in survival was obtained only when using the drug in combination with other chemotherapeutic agents and radiation therapy as first-line treatment of the complex. Bevaсizumab demonstrated ability to reduce peritumoral edema, reducing the need for corticosteroids. Complications in the form of trombophlebitis, hemorrhage, hypertension, delayed wound healing and myelodepression observed relatively rarely, and usually are not fatal character. The findings suggest the advisability of further studies using Bevacizumab with chemoradiation therapy of primary malignant gliomas patients after operation.
Список литературы Бевацизумаб (Авастин®) в терапии опухолей мозга. Обзор литературы
- Von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells.//Clin Cancer Res. 2011. V.17. N19. P.6192-6205.
- Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.//Ann Oncol. 2008. V.19 N4. P. 807-808.
- Burkhardt JK, Riina H, Shin BJ, et al. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.//World Neurosurg. 2012. V.77. N1. P.130-134.
- Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.//Adv Ther. 2011. V.28. N4. P.334-340.
- Couec ML, André N, Thebaud E, et al. Bevacizumab and irinotecan in children with recurrent or refractory brain tumors: Toxicity and efficacy trends.//Pediatr Blood Cancer. 2012. V. 57. N1. P.17-21.
- Cuneo KC, Vredenburgh JJ, Sampson JH, et al. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2012. V.82 N5. P.2018-2024.
- Desjardins A, Reardon DA, Coan A. et al. Bevacizumab and daily temozolomide for recurrent glioblastoma.//Cancer. 2012. V.118. N5. P.1302-1312.
- Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain.//Int J Radiat Oncol Biol Phys. 2007. V. 67. N2. P.323-326.
- Grabner G, Nöbauer I, Elandt K, et al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.//Magn Reson Imaging. 2012. V.30 N.1. P.139-147.
- Gronier S, Bourg V, Frenay M, et al. Bevacizumab for the treatment of cerebral radionecrosis.//Adv Ther. 2011. V.28. N4. P. 334-340.
- Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study.//J Neurooncol. 2008. V.89. N1. P.113-118.
- Guillamo JS, Anti-angiogenic strategies in glioblastoma.//Rev Neurol (Paris). 2011. V.167. N10. P.662-667.
- Hofer S, Elandt K, Greil R, et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.//Acta Oncol. 2011. V.50. N5. P.630-635.
- Jakobsen JN, Hasselbalch B, Stockhausen MTat al. Irinotecan and bevacizumab in recurrent glioblastoma multiforme.// Expert Opin Pharmacother. 2011.V.12. N5. P.825-833.
- Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.//J Neurooncol. 2008. V.89 N1 P.113-118.
- Kreisl TN, Zhang W, Odia Y, et al. A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.//Neuro Oncol. 2011. V.13. N10. P.:1143-1150.
- Kuczynski EA, Patten SG, Coomber BL. VEGFR2 expression and TGF-β signaling in initial and recurrent high-grade human glioma.//Oncology. 2011. V.81. N2 P.126-134.
- Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.//Int J Radiat Oncol Biol Phys. 2009.V. 75 N4. P.1148-1154.
- MacDonald TJ, Aguilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents.//J.Neuro Oncol. 2011. V. 13 N10. P.1049-1058.
- Matuschek C, Bölke E, Nawatny J, et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis.// Strahlenther Onkol. 2011. V.187. N2. P.135-139.
- Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.// J Neurosurg. 2012. V.116. N 2. P.341-345.
- Narayana A, Kunnakkat S, Chacko-Mathew J, et.al. Bevacizumab in recurrent high-grade pediatric gliomas.//Neuro Oncol. 2010. V. 12. N9. P. 985-990.
- Narayana A, Kunnakkat SD, Medabalmi P, et al. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.//Int J Radiat Oncol Biol Phys. 2012.V. 82. N.1. P.77-82
- Norden AD, Bartolomeo J, Tanaka S, et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.//J Neurooncol. 2012. V.106. N1. P.121-125.
- Parekh C, Jubran R, Erdreich-Epstein, et al.Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen.//J Neurooncol. 2011. V.103. N3. P.673-680.
- Peak SJ, Levin VA. Role of bevacizumab therapy in the management of glioblastoma.//Cancer Manag Res. 2010. V. 22. N2. P. 97-104.
- Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.//Pediatr Blood Cancer. 2011. V.56. N12. P.230-234.
- Pu JK, Chan RT, Ng GK, et al. Using bevacizumab in the fight against malignant glioma: first results in Asian patients.//Hong Kong Med J. 2011 V.17. N4. P.274-279.
- Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.//J Neurooncol. 2012. V.107. N1. P.155-164.
- Reismüller B, Azizi AA, Peyrl A, et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors.//Pediatr Blood Cancer. 2010 V. 54. N5. P. 681-686.
- Seet RC, Rabinstein AA, Lindell PE, et al. Cerebrovascular events after bevacizumab treatment: an early and severe complication.//Neurocrit Care. 2011. V.15.N3. P.421-427.
- Specenier P. Bevacizumab in glioblastoma multiforme.// Expert Rev Anticancer Ther. 2012. V.12. N1. P.9-18.
- Vauleon E, Mesbah H, Gedouin D, et al. Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab.//Bull Cancer. 2012. V.99. N2. P.121-126.
- Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.//Oncologist. 2010. V.15. N12. P.1329-1334.
- Wolff JE, Brown RE, Buryanek J, et al. Preliminary experience with personalized and targeted therapy for pediatric brain tumors.//Pediatr Blood Cancer. 2011. V.56 N12. P.55-59.
- Wolff JE, Rytting ME, Vats TS, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.//J Neurooncol. 2012 V.106 N2: P.391-397.
- Wong ET, Gautam S, Malchow C, et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis.//J Natl Compr Canc Netw. 2011. V.9 N4. P.403-407.
